The Museum Tinguely, which was founded in 1996 and is dedicated to the work of the Swiss metal sculptor Jean Tinguely, is a cultural commitment by Roche.
In addition to its permanent exhibition of the machine sculptures and graphic works of Jean Tinguely, who died in 1991, the museum also hosts special exhibitions that give an insight into the art and artists who influenced and were associated with Tinguely, kinetic art and 20th and 21st-century art. Current and past exhibitions have been dedicated to such friends and partners of Tinguely as Niki de Saint Phalle, Yves Klein or Eva Aeppli; to role models such as Marcel Duchamp, Kurt Schwitters or Max Ernst; and to more recent trends such as contemporary kinetic art. Exhibitions always focus on new areas of art. Further information on the Museum Tinguely can be found on its website www.tinguely.ch.
bird's eye jazz club
Basel's bird's eye jazz club enjoys an excellent reputation among jazz musicians the world over, ranking as one of the most highly in-demand and renowned small venues in Europe.
The quality of the acts that perform at bird's eye is correspondingly high. Its line-up of international acts and top Swiss, local or up-and-coming talent offers audiences plenty of variety and encourages international exchanges among musicians. The pleasant and welcoming atmosphere of the city-centre club and the close proximity between audience and performers is highly appreciated by all. In addition to its programme of modern contemporary classical jazz concerts, the club encourages encounters across stylistic boundaries – e.g. with classical, hip-hop or Latin – by taking part in innovative musical projects and networking with other promoters. bird's eye is now an essential and established part of the cultural scene in and around Basel. Further information on bird's eye can found on its website www.birdseye.ch.
(bird's eye jazz club facebook)
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.